How new CLL medicines may leave no patient behind

Published on

Email this program

Get Link

Dr Barbara Eichhorst, a noted chronic lymphocytic leukaemia (CLL) expert from Cologne, Germany, feels the latest news on promising therapies for CLL will benefit a wide group of patients, including those with the most aggressive forms of the disease. Although long-term data is limited, these new agents are often more tolerated and manageable than chemotherapy, and therefore offer new hope for older patients and prospects for lifelong control of disease. Supported by an educational grant from Gilead Sciences Europe through Patient Empowerment Network

View more programs featuring

Page last updated on January 26, 2016